Home
Particles to products, with confidence.
Particology is a UK-based CRO supporting pharmaceutical development teams as they navigate the transition from active molecule to formulated product.
Integration by Design:
Our approach to particle science
Particle properties determine how a drug molecule progresses into a robust, stable and efficacious product. These properties impact many aspects of drug development but rarely get the attention they deserve until something goes wrong.
Particology was built to change that. Our founding team spent their careers in large pharma, applying particle science to the development of new medicines. We’ve since combined that expertise to deliver systematic, stage-appropriate services that help clients get it right without needing to resort to complex and costly formulation solutions.
150+
years of combined pharmaceutical industry experience
100+
projects executed
Global
client base (US, Europe, Asia)
Our team has first-hand experience of working at the highest levels of drug development – across solid form selection, API crystallisation, formulation, commercialisation and filing.
Where we can help
Particle challenges rarely sit neatly within a single discipline. Whatever your challenge, our integrated approach means you get the full picture, not a fragment of it.
Could your solid form screening be doing more to reduce risk and maximise opportunities for development success?
Solid Form Selection
Are your particles engineered to suit your process — or is your process working around your API?
Crystallisation Design & Particle Engineering
Do you have a full picture of how your material’s particle properties will translate to manufacturing performance?
Particle and Powder Characterisation
Are you developing a formulation with a thorough understanding of the material going into it?
Formulation Design
What our clients and partners say
Particology has a wealth of big pharma knowledge and expertise. They immediately understood the task I brought to them and delivered a quality solution. Impressive.
– Dr Gerry Steele, PharmaCryst Consulting Ltd
I have known and worked closely with many members of the Particology team for over 10 years across a range of proprietary and non-proprietary projects and collaborations, and I’m delighted to see that they’re continuing to go from strength to strength. Their expertise and capabilities in particle science are very impressive, and complement CCDC’s informatics-based modelling work perfectly. I see a lot of promise in what we can do together to better support our clients, and I’m looking forward to continuing our partnership over the coming years.
– Dr Andy Maloney, Materials Science Team Lead, CCDC
WHITE PAPER
Why do particle decisions made early on have the greatest impact on downstream development?
If you’re working on a small molecule programme and want to understand where the real risk lies, our white paper is worth a read.
Let’s talk about your programme
Whether you’re facing a specific challenge or are at the early stages of thinking through your drug development strategy, we’re happy to have a conversation. Get in touch and a member of the team will come back to you shortly.
WHEN PARTICLES PERFORM, MEDICINES DELIVER.